GLUE - NASDAQ
Monte Rosa Therapeutics, Inc.
$17.59
-0.85%Monte Rosa Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. It develops an oral molecular glue degrader for GSPT1, a translational termination factor and degron-containing protein for the treatment of Myc-driven cancers. The company also develops CDK2 to treat ovarian, uterine, and breast cancers; NEK7 for the treatment of inflammatory diseases, such as Crohn's disease, neurodegenerative disease, diabetes, and liver disease; VAV1, a target protein for autoimmune diseases; and BCL11A, a therapeutically-relevant protein in hemoglobinopathies. Monte Rosa Therapeutics, Inc. was incorporated in 2019 and is headquartered in Boston, Massachusetts.
At a Glance
Live SnapshotMonte Rosa Therapeutics, Inc. Management Team
Mr. Philip Nickson J.D., Ph.D.
Chief Business & Legal Officer
Compensation
$704,801
Dr. John C. Castle Ph.D.
Chief Data & Information Officer
Dr. Filip Janku M.D., Ph.D.
Chief Medical Officer
Compensation
$743,800
Ms. Jennifer Champoux
Chief Operating Officer
Dr. Sharon Townson Ph.D.
Chief Scientific Officer
Dr. Markus Warmuth M.D.
President, Chief Executive Officer & Director
Compensation
$970,830
Mr. Edmund Dunn
Senior Vice President & Corporate Controller
Mr. Andrew Funderburk
Senior Vice President and Head of IR & Strategic Finance
Mr. Magnus Walter DPHIL
Senior Vice President of Drug Discovery
Monte Rosa Therapeutics, Inc. Insider Positioning
During the last 12 months, insiders have purchased $1.06M and sold $1.66M worth of GLUE shares, resulting in $605K of net selling activity.
3 Months
0
0.00
44.7K
829.17K
-829K
-$829K
3-6 Months
0
0.00
44.2K
830.67K
-831K
-$831K
6-9 Months
0
0.00
0
0.00
+0
+$0
9-12 Months
214.9K
1.06M
0
0.00
+1.1M
+$1.06M
Top Buyers
Behbahani Ali
Director, 10 Percent Owner:
$151K
Manning Anthony M.
Director
$151K
Blackwell Kimberly
Director
$151K
Siu Christine
Director
$151K
Skvarka Jan
Director
$151K
Top Sellers
Warmuth Markus
Director, Officer: President & Ceo
$526K
Dunn Edmund
Officer: Principal Accounting Officer
$467K
Manning Anthony M.
Director
$180K
Janku Filip
Officer: Chief Medical Officer
$179K
Townson Sharon
Officer: Chief Scientific Officer
$119K
Insider Activity Analysis
Net Insider Sentiment
Slightly bearish with $605K net selling. Selling modestly exceeds buying, which could be routine diversification rather than concern.
Buy/Sell Ratio
Moderately negative ratio. Selling is roughly double the buying, which may be routine or signal caution.
Recent Trend (3 Months)
Heavy recent selling activity. Recent insider sales notably exceed purchases—may warrant investigation into company developments.
Insider Participation
5 insider buyers and 5 sellers. Equal participation suggests mixed or neutral insider views.
SEC Filings
GLUE - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2026 N/A | April 29, 2026 | April 29, 2026 | 2026 | |
DEF 14A DEF 14A 2025 N/A | April 25, 2025 | April 25, 2025 | 2025 | |
DEF 14A DEF 14A 2024 N/A | April 26, 2024 | April 26, 2024 | 2024 | |
DEF 14A DEF 14A 2023 N/A | April 26, 2023 | April 26, 2023 | 2023 | |
DEF 14A DEF 14A 2022 N/A | April 27, 2022 | April 27, 2022 | 2022 |
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.